Black Diamond Therapeutics (NASDAQ:BDTX) Downgraded to “Sell” at BidaskClub

BidaskClub lowered shares of Black Diamond Therapeutics (NASDAQ:BDTX) from a hold rating to a sell rating in a report released on Friday, BidAskClub reports.

Separately, Berenberg Bank assumed coverage on shares of Black Diamond Therapeutics in a research report on Tuesday, November 24th. They issued a buy rating and a $58.00 price objective on the stock. One equities research analyst has rated the stock with a sell rating and seven have issued a buy rating to the company’s stock. Black Diamond Therapeutics currently has an average rating of Buy and an average target price of $47.67.

Shares of BDTX opened at $32.05 on Friday. Black Diamond Therapeutics has a 1-year low of $17.63 and a 1-year high of $46.25. The company has a 50-day moving average of $33.48 and a 200 day moving average of $32.51. The firm has a market capitalization of $1.15 billion and a price-to-earnings ratio of -5.30.

Black Diamond Therapeutics (NASDAQ:BDTX) last announced its quarterly earnings data on Sunday, November 15th. The company reported ($0.50) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.52) by $0.02. Equities analysts predict that Black Diamond Therapeutics will post -2.05 EPS for the current year.

In related news, Director Bradley J. Phd Bolzon sold 18,090 shares of the firm’s stock in a transaction on Tuesday, October 6th. The shares were sold at an average price of $33.26, for a total transaction of $601,673.40. Following the sale, the director now owns 8,729 shares in the company, valued at $290,326.54. The transaction was disclosed in a document filed with the SEC, which can be accessed through this link. Also, Director Bradley J. Phd Bolzon sold 18,425 shares of the firm’s stock in a transaction on Thursday, October 8th. The shares were sold at an average price of $33.47, for a total transaction of $616,684.75. Following the sale, the director now owns 10,178 shares in the company, valued at approximately $340,657.66. The disclosure for this sale can be found here. Insiders sold 229,250 shares of company stock worth $7,625,349 in the last quarter.

Hedge funds have recently added to or reduced their stakes in the stock. Windsor Creek Advisors LLC acquired a new stake in Black Diamond Therapeutics during the third quarter valued at $196,000. HC Advisors LLC purchased a new position in Black Diamond Therapeutics during the third quarter valued at $202,000. Raymond James & Associates lifted its holdings in Black Diamond Therapeutics by 4.7% during the third quarter. Raymond James & Associates now owns 7,493 shares of the company’s stock valued at $227,000 after purchasing an additional 333 shares in the last quarter. Amia Capital LLP lifted its holdings in Black Diamond Therapeutics by 55.3% during the third quarter. Amia Capital LLP now owns 7,589 shares of the company’s stock valued at $229,000 after purchasing an additional 2,703 shares in the last quarter. Finally, Schonfeld Strategic Advisors LLC purchased a new position in Black Diamond Therapeutics during the third quarter valued at $244,000. Institutional investors own 61.75% of the company’s stock.

About Black Diamond Therapeutics

Black Diamond Therapeutics, Inc, a precision oncology medicine company, discovers and develops small molecule, tumor-agnostic therapies. Its lead product candidate is BDTX-189, an inhibitor of non-canonical and oncogenic mutations of ErbB kinases epidermal growth factor receptor (EGFR) and tyrosine-protein kinase.

Read More: What Is Dividend Yield and How Do You Calculate It?

Analyst Recommendations for Black Diamond Therapeutics (NASDAQ:BDTX)

Receive News & Ratings for Black Diamond Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Black Diamond Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.